Crestor Cost vs Alternatives in Class: What You Actually Pay and What the Trials Say

How Rosuvastatin (Crestor) Works

Rosuvastatin is a fully synthetic, hydrophilic HMG-CoA reductase inhibitor. It blocks the rate-limiting step of hepatic cholesterol synthesis by competitively inhibiting HMG-CoA reductase, the enzyme that converts HMG-CoA to mevalonate. Less mevalonate means less intracellular cholesterol. The liver responds by up-regulating LDL receptors on its surface, pulling circulating LDL out of the bloodstream.

Hydrophilicity and Hepatic Selectivity

Unlike lipophilic statins such as simvastatin and atorvastatin, rosuvastatin does not diffuse passively into non-hepatic cells. It enters hepatocytes predominantly through the OATP1B1 and OATP1B3 transport proteins, which are highly expressed in liver tissue [1]. This selectivity concentrates the drug where cholesterol synthesis matters most and may reduce off-target effects in muscle tissue, though myopathy remains a class-effect risk at any dose.

Pleiotropic Effects Beyond LDL

The JUPITER trial enrolled 17,802 apparently healthy adults with LDL below 130 mg/dL but high-sensitivity C-reactive protein (hsCRP) at or above 2.0 mg/L [2]. Rosuvastatin 20 mg daily cut LDL by 50%, reduced hsCRP by 37%, and produced a 44% reduction in the primary endpoint of major cardiovascular events compared to placebo (hazard ratio 0.56; 95% CI 0.46 to 0.69; P<0.00001). The trial was stopped early at a median follow-up of 1.9 years because the benefit was so clear. These anti-inflammatory effects are not unique to rosuvastatin, but JUPITER demonstrated them at a scale no other single statin trial had matched for a low-LDL primary-prevention population.

Dose-Response Relationship

Rosuvastatin produces a log-linear LDL reduction. Each doubling of dose adds roughly 6 percentage points of additional LDL lowering, which is the "rule of six" that applies to all statins [3]. Starting at 5 mg, you can expect approximately 38% LDL reduction. At 10 mg, around 43%. At 20 mg, around 48 to 50%. At the ceiling dose of 40 mg, clinical trials report 55 to 63% reduction. This ceiling is higher than any other available statin, including atorvastatin 80 mg, which caps at roughly 50 to 55%.

Rosuvastatin Cost: Brand vs. Generic vs. Competitors

Crestor lost U.S. Patent protection in 2016. Generic rosuvastatin calcium is now manufactured by dozens of companies and is available on most pharmacy $4/$10 lists and GoodRx-discounted programs at cash prices between $10 and $30 for a 30-day supply [4].

Brand-Name Crestor Pricing

AstraZeneca still sells brand Crestor. Without insurance, a 30-tablet supply of Crestor 20 mg typically runs $200, $400 at retail pharmacies. AstraZeneca offers a savings card that can bring out-of-pocket cost to $3/month for commercially insured patients, but Medicare Part D beneficiaries generally cannot use manufacturer coupons. For uninsured patients, the brand carries no practical cost advantage over the generic.

Generic Rosuvastatin Pricing

GoodRx and Cost Plus Drugs (Mark Cuban's pharmacy) both list generic rosuvastatin 20 mg at under $20 for 30 tablets at major chains as of mid-2025. Mark Cuban's Cost Plus Drugs lists rosuvastatin 20 mg (90 tablets) for roughly $13. At that price point, rosuvastatin is among the least expensive high-intensity statins available.

Comparison Table: Monthly Cash Price by Statin

| Statin | Intensity | Typical Dose Range | Approx. Monthly Cash Price (generic) | |---|---|---|---| | Rosuvastatin | High | 20 to 40 mg | $10, $30 | | Atorvastatin | High | 40 to 80 mg | $10, $25 | | Simvastatin | Moderate, High | 20 to 40 mg | $10, $20 | | Pravastatin | Moderate | 40 to 80 mg | $10, $20 | | Pitavastatin | Moderate | 2 to 4 mg | $25, $60 | | Fluvastatin | Moderate | 40 to 80 mg | $30, $80 | | Lovastatin | Moderate | 40 to 80 mg | $10, $20 | | Brand Crestor | High | 20 to 40 mg | $200, $400 |

Prices are approximate U.S. Cash prices and vary by pharmacy and region. All of the generic options are broadly comparable in cost except pitavastatin and fluvastatin, which remain more expensive due to lower generic competition.

Rosuvastatin vs. Atorvastatin: The Primary Clinical Question

For most patients who need high-intensity statin therapy, the real-world choice narrows to rosuvastatin or atorvastatin. Both are generically available, both are cheap, and both have decades of outcomes data.

LDL Reduction Equivalence

A 2009 network meta-analysis by Law et al. In BMJ (N=164 randomized trials, 86,000 patients) established relative potency across the statin class [3]. Rosuvastatin 10 mg produces LDL reductions comparable to atorvastatin 20 mg. Rosuvastatin 20 mg is roughly equivalent to atorvastatin 40 mg. Rosuvastatin 40 mg exceeds the LDL-lowering capacity of atorvastatin 80 mg by approximately 5 to 10 percentage points.

This matters clinically when a patient on atorvastatin 80 mg still has not reached guideline-recommended LDL targets. Switching to rosuvastatin 40 mg may squeeze out an additional 5 to 10 mg/dL of LDL reduction without adding a second agent.

Cardiovascular Outcomes Data

Atorvastatin has more outcomes data by raw volume. ASCOT-LLA (N=10,305) demonstrated that atorvastatin 10 mg reduced fatal and non-fatal coronary events by 36% versus placebo [5]. The 4S trial (N=4,444) showed simvastatin 20 to 40 mg cut total mortality by 30% in secondary prevention [6]. JUPITER, as noted above, established rosuvastatin's outcomes benefit in primary prevention. No head-to-head randomized trial has directly compared cardiovascular mortality between rosuvastatin and atorvastatin at equivalent doses.

Drug Interactions: A Key Differentiator

Atorvastatin is metabolized by CYP3A4. This creates meaningful interactions with azole antifungals, certain HIV protease inhibitors, cyclosporine, and grapefruit juice. Rosuvastatin is not a CYP3A4 substrate. Its metabolism runs primarily through CYP2C9, and plasma levels are affected by OATP1B1 inhibitors (e.g., cyclosporine, certain antiretrovirals) rather than CYP3A4 inhibitors [1]. For patients on complex polypharmacy, this distinction can determine which statin is safer.

Rosuvastatin vs. Simvastatin

Simvastatin was once the world's most-prescribed statin. Its patent expired in 2006, and generic prices bottomed out. Clinically, simvastatin 40 mg produces roughly 37% LDL reduction. Simvastatin 80 mg can achieve approximately 47% LDL reduction, but the FDA issued a 2011 safety communication restricting simvastatin 80 mg to patients who had already been taking it for 12 months without myopathy, based on the SEARCH trial (N=12,064), which found a 0.9% rate of myopathy at the 80 mg dose versus 0.03% at 20 mg [7].

Myopathy Risk Comparison

The hydrophilicity of rosuvastatin is clinically relevant here. Lipophilic statins, including simvastatin, penetrate skeletal muscle more readily. A 2018 analysis in JAMA Internal Medicine found statin-associated muscle symptoms (SAMS) in approximately 5 to 10% of patients across all statins, though nocebo effects account for a substantial portion of those reports [8]. At dose ranges used in most patients (rosuvastatin 10 to 20 mg vs. Simvastatin 20 to 40 mg), the clinical myopathy risk difference is small. At high intensity (rosuvastatin 40 mg vs. Simvastatin 80 mg), rosuvastatin carries a substantially lower regulatory and clinical risk profile.

When Simvastatin Still Makes Sense

Simvastatin 20 to 40 mg remains a reasonable choice for patients who need only moderate LDL reduction, tolerate it well, and are stable on a regimen they understand. Cost is essentially identical to rosuvastatin. Switching a stable patient creates adherence risk without guaranteed clinical benefit.

Rosuvastatin vs. Pravastatin

Pravastatin is the statin of choice in specific patient populations. It is hydrophilic, has minimal CYP metabolism, and carries a well-documented safety profile in patients with HIV on antiretroviral therapy (because most protease inhibitors do not significantly affect pravastatin levels) [9].

Pregnancy and Pediatric Considerations

The 2021 ACC/AHA Guideline on Prevention of Cardiovascular Disease notes that statin therapy is generally contraindicated during pregnancy [10]. Pravastatin has historically been considered when inadvertent statin exposure in pregnancy requires a risk discussion, though no statin is considered safe in pregnancy. In pediatric familial hypercholesterolemia, pravastatin 20 to 40 mg has the most pediatric trial data and an established FDA-approved indication in children as young as 8 years [11].

LDL-Lowering Potency

Pravastatin is a moderate-intensity statin. The maximum dose of 80 mg produces approximately 30 to 37% LDL reduction, well below what rosuvastatin 10 to 20 mg can achieve. For patients who need high-intensity therapy, pravastatin is not a suitable alternative.

Rosuvastatin vs. Pitavastatin

Pitavastatin (Livalo, Zypitamag) is the newest member of the statin class approved in the U.S. (2009). It is minimally metabolized by CYP enzymes, making it appealing in polypharmacy settings, and it does not raise blood glucose to the same degree as other statins in some observational analyses.

REAL-CAD Trial Evidence

The REAL-CAD trial (N=13,054, published in JAMA 2018) compared pitavastatin 4 mg versus 1 mg in Japanese patients with stable coronary artery disease and found that the higher dose reduced the composite cardiovascular endpoint by 19% [12]. This is the primary outcomes trial for pitavastatin and establishes efficacy, though the trial population was ethnically homogeneous.

Cost Disadvantage

Generic pitavastatin is available but commands higher prices than rosuvastatin or atorvastatin. Most GoodRx-discounted prices for pitavastatin 4 mg run $25, $60/month versus $10, $20 for rosuvastatin. Unless a patient has a specific indication for pitavastatin (e.g., statin-associated new-onset diabetes concern, specific drug interactions), the cost differential is difficult to justify.

Statin Intensity Classification and Guideline Targets

The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol classifies statins into three intensity categories based on expected LDL reduction [13]:

• High intensity: LDL reduction 50% or more. Includes rosuvastatin 20 to 40 mg and atorvastatin 40 to 80 mg.
• Moderate intensity: LDL reduction 30 to 49%. Includes rosuvastatin 5 to 10 mg, atorvastatin 10 to 20 mg, simvastatin 20 to 40 mg, pravastatin 40 to 80 mg, and pitavastatin 2 to 4 mg.
• Low intensity: LDL reduction below 30%. Includes simvastatin 10 mg, pravastatin 10 to 20 mg, lovastatin 20 mg.

The guideline's four primary patient groups for statin therapy are: (1) clinical ASCVD, (2) LDL-C 190 mg/dL or higher, (3) diabetes aged 40 to 75 with LDL-C 70 to 189 mg/dL, and (4) primary prevention with 10-year ASCVD risk 7.5% or higher. For groups 1 and 2, high-intensity statin therapy is the default. This makes rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg the first-line options by guideline standard.

As the 2018 ACC/AHA guideline directly states: "High-intensity statin therapy should be initiated or continued as first-line therapy in patients with clinical ASCVD" [13].

Rosuvastatin Dosing Across Populations

Asian Patients

Rosuvastatin plasma concentrations are approximately 2-fold higher in patients of Asian descent compared to Caucasian patients, likely due to OATP1B1 pharmacogenomic variation. The FDA label recommends initiating at 5 mg daily in Asian patients and using caution at 40 mg [4]. This is the one population where starting dose differs meaningfully from general practice.

Renal Impairment

For patients with severe renal impairment (eGFR <30 mL/min/1.73m²) not on dialysis, the FDA label caps rosuvastatin at 10 mg daily [4]. Other statins, particularly atorvastatin (which is predominantly hepatically cleared), do not carry the same renal dosing restriction, making atorvastatin a potential advantage in advanced CKD.

Elderly Patients

No specific dose adjustment is required for age alone, but the 2018 ACC/AHA guideline recommends clinician-patient discussion about statin intensity in adults over 75, balancing ASCVD risk reduction against polypharmacy burden and frailty [13].

Side Effects: What the Trials Actually Show

The most common adverse effects of rosuvastatin in clinical trials are headache, myalgia, and gastrointestinal symptoms, each occurring in roughly 3 to 6% of patients in placebo-controlled studies [2]. Three specific risks deserve precise numbers.

Myopathy and Rhabdomyolysis

Rhabdomyolysis is rare across the statin class. The FDA adverse event database and large observational studies estimate rhabdomyolysis at roughly 1.5 per 100,000 person-years for high-intensity statins [8]. CK elevation above 10 times the upper limit of normal (the clinical threshold for statin-associated myopathy) occurs in under 0.5% of patients on therapeutic rosuvastatin doses.

New-Onset Diabetes

A 2010 meta-analysis by Sattar et al. In The Lancet (N=91,140 across 13 statin trials) found statins increase new-onset type 2 diabetes by 9% overall, with no clear difference between agents [14]. The JUPITER trial itself showed a statistically significant increase in physician-reported diabetes in the rosuvastatin arm (3.0% vs. 2.4% placebo) [2]. The absolute risk increase is small and is outweighed by cardiovascular benefit in high-risk patients.

Hepatotoxicity

Clinically significant liver injury from statins is rare. A systematic review published in Hepatology estimated serious drug-induced liver injury from statins at 1 to 3 per 100,000 person-years [15]. Routine baseline ALT measurement is no longer recommended before initiating statins in the 2018 ACC/AHA guideline, though symptomatic liver disease warrants investigation.

When to Choose Rosuvastatin Over Competitors

The decision is not arbitrary. Consider rosuvastatin first when:

A patient needs high-intensity therapy and is on a CYP3A4-interacting drug (azole antifungal, HIV PI, clarithromycin). Atorvastatin's CYP3A4 metabolism creates a real interaction risk; rosuvastatin does not share this liability.

A patient on atorvastatin 80 mg has not reached an LDL target below 70 mg/dL for secondary prevention. Switching to rosuvastatin 40 mg may close that gap without adding ezetimibe.

A patient has prior statin intolerance attributed to lipophilic agents (simvastatin, atorvastatin). The hydrophilic profile of rosuvastatin gives a rational basis for a re-trial, though the evidence that hydrophilicity independently reduces SAMS risk is associative rather than causal [8].

Consider atorvastatin instead when a patient has eGFR <30 and needs high-intensity therapy, or when the prescribing clinician prioritizes the larger raw volume of outcomes trial data behind the atorvastatin molecule.

Consider pravastatin when a patient is on HIV antiretroviral therapy with significant CYP and OATP interactions that make both rosuvastatin and atorvastatin difficult to dose safely [9].

Combination Therapy: Rosuvastatin Plus Ezetimibe

When a single statin at maximum tolerated dose does not reach LDL targets, ezetimibe is the first add-on by guideline recommendation [13]. The IMPROVE-IT trial (N=18,144) showed that adding ezetimibe 10 mg to simvastatin 40 mg after acute coronary syndrome reduced the primary composite cardiovascular endpoint by an absolute 2.0% (relative reduction 6.4%) over 7 years [16]. Although IMPROVE-IT used simvastatin rather than rosuvastatin as the backbone, ezetimibe's mechanism (inhibiting intestinal cholesterol absorption via NPC1L1) is additive to any statin. Rosuvastatin-ezetimibe fixed-dose combination tablets are available as generic Roszet and as brand Roszuzet, typically priced at $30, $80/month for the generic combination.

For patients who remain above LDL targets on maximum-intensity statin plus ezetimibe, PCSK9 inhibitors (evolocumab, alirocumab) are next in line, though their monthly cost of $400, $600 before negotiation remains a barrier without prior authorization.